Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.
Assessing the Role of Cannabis in Managing Spasticity in Multiple Sclerosis: A Systematic Review and Meta-Analysis
Authors: Yazan AlHabil, M.D. ,Liza Saadeddin1, Hana Ishkirat, Mariam Alqam, Obada Hossoon, M.D., Seema Hameedi, M.D, Hamzeh Yacoub, M.D., Diana Yasin, Anita Bahbah, Majd Oweidat, M.D., Hanadi Mosa Published 1…
Machine-learning of medical cannabis chemical profiles reveals analgesia beyond placebo expectations
Authors Adi Hatav, Yelena Vysotski, Anna Shapira, Shiri Procaccia, David Meiri & Dvir Aran Published 16 July 2025
Association of Cannabis Use With Cardiovascular Outcomes Among US Adults
We examined the association between cannabis use and cardiovascular outcomes among the general population, among never‐tobacco smokers, and among younger individuals.
Fixed combination of palmitoylethanolamide and melatonin in preventive therapy of migraine: results from a randomized clinical trial
Migraines are neurological disorders which significantly impact quality of life. Current pharmacological treatments often have adverse effects, prompting the search for alternatives with fewer side effects. Several studies have described the antimigraine properties of palmitoylethanolamide (PEA) and melatonin.
Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants—A Double-Blind Randomised Controlled Study
Migraines are a common neurological disorder that generally affects young to middle-aged adults and females more than males. Various treatment options are available; however, these can cause undesirable side effects. Therefore, alternative treatments with minimal side effects are still being investigated. Palmitoylethanolamide (PEA) is a signalling lipid known to have anti-inflammatory and analgesic properties. Previous prophylactic research has reported PEA supplementation to decrease pain associated with migraines. Upon commencement of migraine symptoms, participants were supplemented with either 600 mg of PEA (Levagen+) or a placebo (maltodextrin). Once a dose was taken, participants recorded a visual analogue scale (VAS) for pain every 30 min for 4 h or until the migraine resolved.